Variable | HIV-negative | HIV-infected, | HIV-infected, |
---|---|---|---|
Proportion (%) | control | ART-naive | on ART |
Median [IQR] | (number = 153) | (number = 151) | (number = 150) |
Female | 94 (61.4%) | 89 (58.9%) | 115 (76.7%) |
Age (in years) | 38 [32 to 46] | 37 [32 to 44] | 40 [38 to 47] |
Education level | Â | Â | Â |
Incomplete primary | 27 (17.7%) | 25 (16.6%) | 30 (20.0%) |
Complete primary | 82 (53.6%) | 98 (64.9%) | 94 (62.7%) |
Secondary and above | 44 (28.8%) | 28 (18.5%) | 26 (17.3%) |
Work type | Â | Â | Â |
Manual | 109 (71.2%) | 114 (75.5%) | 105 (70.0%) |
Office | 44 (28.8%) | 37 (24.5%) | 45 (30.0%) |
Vigorous work | 15 (9.8%) | 21 (13.9%) | 33 (22.0%) |
Mode of transportation | Â | Â | Â |
Walking or bicycle | 130 (85.0%) | 110 (72.9%) | 117 (78.0%) |
Motorized vehicle | 23 (15.0%) | 41 (27.1%) | 33 (22.0%) |
Ease of Living Index a | Â | Â | Â |
Low | 86 (56.2%) | 94 (62.3%) | 81 (54.0%) |
Middle | 20 (13.1%) | 24 (15.9%) | 26 (17.3%) |
Higher | 47 (30.7%) | 33 (21.9%) | 43 (28.7%) |
Ever smoking | 6 (3.9%) | 16 (10.6%) | 10 (6.7%) |
Current smoker | 5 (3.3%) | 4 (2.7%) | 0 |
Fruit and vegetables servings/week | 6 [4-12] | 8 [5-12] | 9 [6 to 13] |
Sugary drinks/day | 1 [0.5 to 2] | 1 [0.5 to 2] | 1 [1 to 2] |
Current alcohol use | Â | Â | Â |
None | 119 (77.8%) | 120 (79.5%) | 136 (90.7%) |
< once/week | 19 (12.4%) | 16 (10.6%) | 8 (5.3%) |
≥ once/week | 15 (9.8%) | 15 (9.9%) | 6 (4.0%) |
Body Mass Index (BMI) in kg/m 2 | 23.8 [22.3 to 25.8] | 22 [20.2 to 24.3] | 23.7 [21.5 to 27.9] |
BMI <18.5 | 5 (3.3%) | 18 (11.9%) | 4 (2.7%) |
BMI 18.5 to 25 | 104 (68.0%) | 113 (74.8%) | 80 (53.3%) |
BMI 25 to 30 | 33 (21.6%) | 9 (6.0%) | 45 (30.0%) |
BMI >30 | 11 (7.2%) | 11 (7.3%) | 21 (14.0%) |
Waist-hip ratio | 0.84 [0.82 to 0.87] | 0.84 [0.80 to 0.89] | 0.87 [0.82 to 0.91] |
Central obesity b | 44 (29.1%) | 56 (37.1%) | 78 (52.0%) |
Diabetes mellitus | 0 | 1 (0.7%) | 1 (0.7%) |
Current CD4 T-cell count in cells/μL | NA | 215 [150 to 321] | 378 [263 to 521] |
Nadir CD4 T-cell count in cells/μL | NA | 209 [120 to 302] | 118.5 [68 to 196] |
ART duration (months) | NA | NA | 56 [31 to 68] |
Protease inhibitor use | NA | NA | 18 (12.0%) |